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The Relevance of Gynecologic 
Oncologists to Provide High-Quality 
of Care to women with Gynecological 
Cancer
Lucas Minig* , Pablo Padilla-Iserte and Cristina Zorrero
Gynecology Department, Valencian Institute of Oncology (IVO), Valencia, Spain
Gynecologic oncologists have an essential role to treat women with gynecological can-
cer. It has been demonstrated that specialized physicians who work in multidisciplinary 
teams to treat women with gynecological cancers are able to obtain the best clinical and 
oncological outcomes. However, the access to gynecologic oncologists for women with 
suspected gynecological cancer is scarce. Therefore, this review analyzes the impor-
tance of specialized care of women with ovarian, cervical, and endometrial cancer. In 
addition, the role of gynecologic oncologists who offer fertility-sparing treatment as well 
as their role in assisting general gynecologists and obstetricians is also reviewed.
Keywords: gynecologic oncologists, ovarian cancer, vulvar cancer, endometrial cancer, cervical cancer, 
centralization of care, fellowship-training program
inTRODUCTiOn
It is estimated that over a million new cases and half million deaths are due to gynecological cancers 
that occur annually worldwide (1). Even though general gynecologists commonly treat these diseases 
across the world, the sub-specialization in gynecologic oncology has been progressively increasing 
in developed countries since 1972 (2, 3).
According to the definition of the American Board of Obstetrics and Gynecologist, gynecologic 
oncologist is “a specialists in obstetrics and gynecology who is prepared to provide consultation on 
comprehensive management of patients with gynecologic cancer and who works in an institutional 
setting wherein all the effective forms of cancer therapy are available” (4).
Gynecologic oncologists have an essential role when treating women with gynecological cancer. 
They are in a unique position to enrich the global health community with opportunities for education, 
training, and policymaking as it pertains to women’s cancers. In addition, they are in a privileged 
position to make decisions regarding the integration and sequencing of all modalities of treatment.
Specialized physicians who work in multidisciplinary teams to treat women with gynecological 
cancers obtain the best clinical and oncological outcomes (5–7). We think that by this approach, 
gynecologic oncologists not only play an important role in performing an optimal surgery but they 
can also provide a better overall quality of care by having a holistic conception of women. However, 
in countries with a high number of gynecologic oncologists, only a minority of women with 
gynecological cancer receives care by specialized physicians at referral institutions (8). For example, 
it has been demonstrated that approximately one-third of women with ovarian cancer are treated 
by gynecologic oncologists in the U.S. Therefore, this article will review the role of gynecologic 
oncologists who treat women with different gynecological malignancies.
FiGURe 1 | Multidisciplinary team to treat women with gynecological 
cancer.
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OvARiAn CAnCeR
Ovarian cancer probably represents the best example of how a 
well-prepared specialist can positively modify the clinical and 
oncologic outcomes of women. Ovarian cancer is the most aggres-
sive gynecological cancer with a 5-year overall survival of 40% 
(9). There are well-documented independent prognostic factors 
at advanced-stage disease, including tumor histology and grade 
of differentiation, patient’s age, stage of disease, performance 
status, and surgical debulking (10). However, the latter is the 
only modifiable factor, which means that it is amenable for direct 
influence, and therefore, seems to be of the utmost importance 
when considering efforts aiming toward improving outcomes of 
this disease.
The relevance of an adequate surgery was highlighted in 
multiple studies, which associated a significant improvement 
in oncological outcomes after a complete tumor resection at 
the time of primary surgical cytoreduction in comparison with 
cases in which there was some amount of residual disease at the 
end of the surgical procedure (9–11). Thus, according to the last 
Gynecological Cancer InterGroup (GCIG) consensus conference, 
“the mainstay of treatment of advanced ovarian cancer is primary 
surgery aiming at complete tumor resection followed by platinum 
and paclitaxel chemotherapy” (12).
However, the final decision as to whether or not to perform a 
tumor debulking depends on the surgeon’s training and confidence 
(13). Many studies suggest that patients operated on by gynecologic 
oncologists with previous training in cytoreductive techniques are 
more likely to undergo an adequate surgical staging in the early 
stage of the disease, and a better rate of complete cytoreduction 
in advanced stages in comparison with those patients treated by 
general gynecologists or general surgeons (5–7). More specifically, 
when gynecologic oncologists perform the surgery, there are twice 
as many probabilities of obtaining a complete cytoreduction (5). As 
a consequence, according to the results of meta-analyses, patients 
operated on by gynecologic oncologists have significantly better 
oncological outcomes, which resulted in an increased overall 
survival of 10 months, in comparison with those patients treated 
by general gynecologist or general surgeons (5–7).
A recent document launched by the European Society of 
Gynecological Oncology (ESGO) regarding the quality indica-
tors in ovarian cancer surgery states that “Surgery is performed 
by a certified gynecologic oncologist or, in countries where 
certification is not organized, by a trained surgeon dedicated 
to the management of gynecologic cancer (accounting for over 
50% of his practice) or having completed an ESGO accredited 
fellowship. Skills to successfully complete abdominal and pelvic 
surgery procedures necessary to achieve complete cytoreduction 
must be available” (14).
However, ovarian cancer surgery is not an easy task, and it 
requires an adequate institutional support, as well as establishing 
evidence-based clinical guidelines. Even though gynecologic 
oncologists should lead these surgeries, it is recommended to 
work in a multidisciplinary surgical team involving other special-
ists, such as general surgeons, anesthesiologists, and infectologist. 
This strategy is aimed to offer the best quality of care for the 
patient (Figure 1).
enDOMeTRiAL CAnCeR
The majority of endometrial cancers are low-risk disease with 
excellent oncological outcomes (15). Thus, the potential positive 
impact of subspecialty care in endometrial cancer might be more 
difficult to demonstrate (16). However, gynecologic oncologists 
can have an important role in the implementation of minimally 
invasive surgery with their well-known advantages over open 
surgery (17). In this regard, a recent U.S. epidemiological study 
demonstrated that 86% of robotic surgeries for endometrial 
cancer were performed in 19% of the analyzed hospitals. Each 
additional 25 patients (above the mean surgical volume) were 
associated with over a 2.5-fold increase in odds of robotic surgery 
(OR = 2.65, 95% CI: 1.82–3.86; p < 0.0001) (17).
In addition, another epidemiology study performed in the 
U.S. evaluated 18,338 women with endometrial cancer, 4,489 
of whom at stages II–IV (24.3%) (18). Patients who underwent 
surgery by a gynecologic oncologist were more likely to receive 
a more extensive lymph node resection (16 lymph nodes; 22 
vs. 17%; p < 0.001), have more aggressive histologic cell types, 
such as serous and clear-cell (11.6 vs. 6.1%; p < 0.001), presented 
with advanced-stage disease (stages III and IV; 21.9 vs. 14.6%; 
p < 0.001), were more likely to received chemotherapy (22.6 vs. 
12.4%; p < 0.001), as well as to received radiotherapy (38.9 vs. 
30.7%; p < 0.001). In addition, surgery performed by gynecologic 
oncologist was an independent prognostic factor and was associ-
ated with a 30% increase in overall survival in comparison with 
other type of surgeons (HR, 0.71; 95% CI, 0.62–0.82; p < 0.001) 
(18). Other studies did not find significant differences in the 
survival rate, probably because they only included early-stage 
disease (19), or due to the fact that they only analyzed a small 
number of patients (16, 19).
CeRviCAL CAnCeR
Worldwide, cervical cancer accounts for over 500,000 cases and 
275,000 deaths each year (20). However, there is a great disparity 
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among high- and low-income countries due to successful imple-
mentation of cervical cancer screening programs in developed 
countries (21). In addition, the reduction in the incidence of 
cervical cancer should continue with the increased use of human 
papilloma virus (HPV) vaccination (22). Therefore, the majority of 
women with cervical cancer in developed countries are diagnosed 
at early stages with a 5-year overall survival rate of over 90% (23).
No studies have specifically addressed the impact on survival 
of women with early-stage cervical cancer treated by gynecologic 
oncologists. One U.S. epidemiological study, however, studied 
27,660 women with cervical cancer FIGO stage IIB–IVB who were 
treated at hospitals with different case volumes. The study showed 
that the median rate of survival of patients treated at the lowest 
and highest volume centers were 42.3 months (95% CI 39.8–44.8) 
and 53.8 months (50.1–57.5), respectively (p < 0.001). On multi-
variable analysis, higher facility volume independently predicted 
improved survival (p = 0.022), increased likelihood of receiving 
brachytherapy (p < 0.0005) and chemotherapy (p = 0.013), as well 
as shorter time to radiotherapy completion (p < 0.0005) (24).
vULvAR CAnCeR
Squamous cell cancer of the vulva is a rare disease with an annual 
incidence of 2–3/100,000 women (25). There is evidence that 
demonstrates step-by-step nodal metastases in human cancer 
(26). Therefore, the first regional lymph node, called sentinel node, 
receiving lymphatic fluid from the tumor is initially removed. All 
regional lymph nodes are only dissected in case of disease in the 
sentinel node. Thus, this technique significantly reduces the inci-
dence of postoperative complications, such as wound breakdown 
or cellulitis, and long-term morbidity including lymphedema 
(27). However, failure in the sentinel node detection is mainly 
seen when specialists with low case-volume (<10 cases/year) 
perform the procedure (27). Failure of this procedure can mean 
leaving the sentinel node in place, probably with tumor cells and 
with fatal consequences for patients. Therefore, some authors 
recommend that sentinel node detection in patients with vulvar 
cancer should be offered to well-selected patients by well-trained 
and informed gynecologic oncologists who work in centers 
with at least 10 cases/year (27, 28). In addition, it is also recom-
mended that this technique be performed by multidisciplinary 
team involving gynecologic oncologists, specialists in nuclear 
medicine, and specialized pathologists (27).
ROLe OF GYneCOLOGiC 
OnCOLOGiSTS in SPeCiAL 
CiRCUMSTAnCeS
Fertility Preserving Treatment in women 
with Gynecological Cancers
It is estimated that over 21% of women with gynecological cancer 
are diagnosed in their reproductive age (29). In addition, it has 
been demonstrated a continuum increase of women age at first 
pregnancy (30, 31). Both factors explain why fertility preservation 
in women with gynecological cancer is currently a very important 
issue. The recommended treatment for the great majority of 
gynecological cancer includes radical removal of the uterus and 
ovaries, annulling any possibility for future pregnancies. However, 
fertility-sparing treatment in young patients with women’s cancer 
is possible in very select women without compromising long-term 
survival (32). A recent survey of the ESGO revealed that only a 
minority of young women candidates to fertility-sparing treat-
ment is aware of the opportunity to preserve their fertility (33). 
The main reasons include the surgeon’s being unaware, skeptic, or 
untrained to perform fertility-sparing surgical procedures (33). 
Despite the fact that fertility-sparing surgery is technically not 
difficult (except for radical trachelectomy for cervical cancer), a 
more complicated task can be to select the appropriate candidate 
for such specific treatment. Therefore, according to an ESGO 
statement, these patients should be managed in a multidisciplinary 
team coordinated by gynecologic oncologists in conjunction with 
medical reproductive endocrinologists, perinatologists, patholo-
gist, psychologists, and assisted reproductive specialists (33).
Surgical Assistance to General 
Gynecologists and Obstetricians
Even though gynecologic oncologists are intensively trained in 
all aspects of women’s cancer care, their main area of expertise is 
focused on performing complex surgical procedures. Therefore, 
their role in clinical practice often extends beyond women’s can-
cer. For instance, they can be of assistance to general gynecolo-
gists/obstetricians at certain moments during difficult surgical 
procedures, such as being a surgical resource to obstetricians 
during challenging peripartum hemorrhage, (34–36) as well as 
in cases of complex pelvic anatomy or pathological placenta-
tion (37). A recent study performed at Massachusetts General 
Hospital revealed that gynecologic oncologists can assist general 
gynecologists at the time of intraoperative consultation in 98 
out of 794 benign gynecological surgical procedures (12.3%). 
The main reasons for unplanned consultation included adhesive 
disease, bowel injury, ureter visualization, cancer, and bleeding 
control (34).
CenTRALiZATiOn OF CARe – 
MULTiDiSCiPLinARY MAnAGeMenT
Gynecological cancer is a challenging, complex, and multidis-
ciplinary disease. It is not only important how well trained the 
physicians are but also how many physicians of different special-
ties are involved (38). The concept of the holistic conception of 
patient care under a multidisciplinary team approach is crucial 
from the diagnosis to the demise of the disease, and this model 
should not be restricted to the operating room setting.
A correct collaboration with dedicated pathologists, medical 
oncologists, radiotherapists, biologists, palliative care specialists 
might help avoid unnecessary mismanagements, and therefore, 
reinforce the holistic conception of patients with gynecological 
cancer with an improvement on their perceived quality of care. 
Moreover, the recent molecular biology, genetic, and immunol-
ogy discoveries are opening new optimistic frontiers for the future 
treatment and cure of this disease. Many authors agree that close 
exchanges between the clinical practice and basic research are 
FiGURe 2 | Multidisciplinary care in a gynecological cancer unit.
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crucial for consolidating these progresses (39, 40) (Figure 2). A 
recent meta-analysis demonstrated that women with gynecologi-
cal malignancies who receive care from a multidisciplinary team 
by specialized physicians live for a significantly longer period of 
time (7).
Centralization of care in women with gynecological cancer 
is another crucial issue. In some regions, gynecologic oncology 
cases have been centralized (41) in centers with higher patient 
volumes and interdisciplinary collaboration (42). These centers 
receive referrals from less-specialized hospitals within a network, 
region, or defined catchment area. Under this model of care, 
women are referred to specialized units, which are a team built 
by multiple specialized physicians focused on the comprehensive 
care of women affected by gynecological cancer. Every case is 
discussed inside in a multidisciplinary tumor board where the 
best strategy of treatment is based on multiple points of views, 
taking into consideration all aspects regarding each individual 
patient expectancy beyond the disease itself (Figure 2).
Results of different studies consistently show that patients with 
ovarian cancer treated at high-volume hospitals receive better 
quality of care, which is accomplished by better surgical staging 
and better optimal cytoreduction rate (5–7), as well as better 
chemotherapy administration rate and schemes (43, 44).
One study, performed in England, showed that the survival 
of patients with gynecologic cancer improved significantly after 
centralization in comparison with the pre-centralization period 
(hazard ratio: 0.71; 95% confidence interval: 0.64–0.79) (45). 
Similar findings were also reported for cervical, endometrial, 
and ovarian cancer after the implementation of the U.K. National 
Health Service cancer plan in 2000 (46).
Despite the consensus recommendations (12) and the advan-
tages previously explained, population-based studies indicate 
that access to specialist care in gynecologic oncology for women 
with suspected gynecological cancer is uncommon (47–49). 
Reports from countries such as U.S. (8, 50) and U.K. (49, 51) have 
showed that over 60–80% of patients with advanced stage ovar-
ian cancer are treated in low-volume hospitals by low-volume 
surgeons (8, 52, 53).
Common barriers to the quality of cancer care have been 
identified by multiple investigators and include the extremes of 
age, minority race, low socioeconomic status, rural residence, 
patient’s and physician’s unawareness of gynecologic oncologist 
resources, ineffective recognition of the disease, and third-party 
payers (8, 47).
FeLLOwSHiP-TRAininG PROGRAM
Gynecologic oncologists have also an important role in teach-
ing and educating fellow colleagues. Physicians who want to 
be gynecologic oncologists need to undergo a long and specific 
period of training and education process. After finishing medi-
cine school, physicians must complete a 4- to 5-year residency-
training program in obstetrics and gynecology. Then, they need 
to be accepted in accredited referral institutions to complete their 
specific fellowship-training program for 2–4 more years. The 
training, skills, and knowledge base required of a gynecologic 
oncologist are rapidly expanding. In addition to the original areas 
of radical pelvic surgery, chemotherapy, radiation therapy, and 
pathology, new areas of training include radical upper abdominal 
surgery, minimally invasive and robotic surgery, translational 
medicine and research, and palliative medicine (54).
In 1972, the first gynecologic oncologic fellowship-training 
programs were introduced in the U.S. with two accredited fel-
lowships. Since then, 46 fellowship programs exist with 126 
approved positions (55). Currently, there is a uniform system 
of training developed by the American Board of Obstetrics and 
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Gynecologist who provide the training resource documents for 
the development of a curriculum in gynecologic oncology (4). 
Australia, Canada, U.K., and recently, the European Union are 
other examples of renowned gynecologic oncologic fellowship-
training programs around the world (2). However, the number 
of gynecologic oncologists per patient is still scarce worldwide, 
and it is expected that the number of fellowship positions will 
continue to increase through the following years (56).
COnCLUSiOn
When women with gynecological cancers are treated by gyneco-
logic oncologists in referral cancer centers, they are able to 
live longer and with a better quality of life. Therefore, patients 
should be ideally referred to high-volume physicians/hospitals 
to increase their life expectancy as well as its quality. Expanding 
fellowship-training programs worldwide as well as highlighting 
the existence and relevance of gynecologic oncologists in the 
general population and medical community is crucial to increase 
the patient’s accessibility to a specialist’s care.
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